The first FDA-approved multi-gene testing (Guardiant360 CDx assay) on cfDNA, which aims at detecting EGFR mutations in patients affected by NSCLC who can benefit from the use of osimertinib, dates to August 2020 [136]. Here, EGFR is linked to non-small cell lung carcinoma.